Jean-Sylvain Perrig, Chairman of the Board since 5 March 2019.
Jean-Sylvain Perrig is the founder of Premyss SA whose role is to help financial intermediaries having an efficient, transparent and documented investment process which foster risk-adjusted performances.
Jean-Sylvain is the chairman of the board of the Swiss Financial Analysts Association (SFAA) which provides education to investment professional, he is the former CIO of Edmond de Rothschild Private Bank and Union Bancaire Privée (UBP).
Jean-Sylvain holds a master degree in Economics from the University of Lausanne, and a Federal Diploma of Financial Analyst.
Sandy Koifman, Vice Chairman of the Board since 5 March 2019.
Sandy Koifman is co-founder of Efficient Frontier Investing SA, in November 2018. Sandy formerly established Bedrock SA, an independent wealth management company in Geneva as Managing Director. He was a Senior Investment Consultant with IRR Capital.
Prior to that, Sandy was General Manager of the Republic National Bank of New York, Treasurer of Safra Republic Holdings, Chairman and CEO of the Republic Group's fund management arm and member of Executive, Credit and Treasury Committees.
Sandy holds several board seats, leveraging his wealth of experience in the world of finance.
Dr Jonas Richiardi, Member of the Board since 5 March 2019.
Dr Jonas Richiardi has been working in technology R&D for more than 15 years, with a focus on machine learning and artificial intelligence. After earning his MPhil from Cambridge, UK and his PhD from EPFL, Switzerland, he spent two years at Stanford as a Marie Curie Fellow.
He co-founded the engineering consultancy PatternLab in Switzerland in 2007, which focuses on applied machine learning for international customers, and is currently working as a clinical research lead at the Lausanne University Hospital, developing AI solutions for radiology.
Stefano Rodella, Member of the Board since 5 March 2019.
Stefano Rodella is the founder and CEO of AtonRâ Partners.
Stefano has 25 years of experience in Financial Markets at a whole, with a clear emphasize on independent fundamental research on technologies, pharmaceutical & biotechnology and commodities sectors.